Following on from information provided to NICE by the company in March 2016, the appraisal of Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Selected
- Process:
- TA
- ID number:
- 897
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Stakeholders
- Companies sponsors
- Bayer (sorafenib)
- Novartis Pharmaceuticals (everolimus)
- Pfizer (axitinib and sunitinib)
- Others
- Department of Health
- NHS England
- Welsh Government
- Patient carer groups
- Kidney Cancer Support Network
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Associated public health groups
- None
- Comparator companies
- None
- General commentators
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Relevant research groups
- National Cancer Research Institute
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 January 2023 | Discontinued. Following on from information provided to NICE by the company in March 2016, the appraisal of Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 31 March 2016 | Suspended. Following a series of changes to the technologies due to be appraised, NICE considers there is limited value to the NHS in conducting an MTA of the remaining second line renal cell carcinoma therapies (axitinib, sorafenib and sunitinib). The Institute has decided to remove this appraisal from its current work programme. |
| 09 February 2016 | Invitation to participate |
| 19 January 2016 | Invitation to participate |
For further information on our processes and methods, please see our CHTE processes and methods manual